Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

This review discusses diagnostic and treatment considerations for women with cutaneous hyperandrogenism, noting therapeutic options are more effective for hirsutism and acne than for androgenetic alopecia, but reports no new clinical results.

This review describes the clinical signs, symptoms, and diagnostic findings for alopecia frontal fibrosante, emphasizing the importance of early diagnosis and variable treatment options, and reports no new findings.

This study introduced a Density-Calibrated Airtouch Protocol (DCAP) that suggests customizing the Airtouch hair coloring technique based on client hair density to optimize color blend, pigment longevity, and hair health.

This review discusses fibrosing frontal alopecia, including its causes, mechanisms, and treatments, and emphasizes the need for further research to improve understanding and treatments; it reports no new clinical results.

This research describes the synthesis of 16β-chloro- and 16β-bromo-cyproterone acetate, detailing the chemical processes involved, but reports no clinical outcomes.

In this clinical trial, adding topical calcipotriol to intralesional triamcinolone acetonide significantly increased hair regrowth efficacy in scalp alopecia areata patches compared to steroids alone, but not in beard patches, with a lower incidence of atrophy observed.

This study reports on a patient whose symptoms, including trichoepitheliomas and clinical alopecia, may suggest a new syndrome possibly linked to myasthenia gravis.

This study found that DNA methylation and histone modification status were altered in peripheral blood mononuclear cells of patients with alopecia areata, suggesting these changes may contribute to the disease's pathological immune responses.

This article discusses the characteristics of alopecia areata but reports no new research results.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

This study found that menstrual irregularity is common in women with acromegaly, with high GH levels, estrogen deficiency, and larger tumors correlating with more severe irregularity.

Baricitinib helps with early hair regrowth in people with alopecia areata.

People with certain allergic conditions or higher white blood cell counts have more severe hair loss, and treating hair and nail side effects early in melanoma therapy can improve quality of life.

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

In this in-vitro study, researchers found that shampoo-induced coacervates structurally resemble cationic polymers and contain anionic surfactants that may stimulate the scalp upon exposure to water.

This study describes a case where a patient with alopecia totalis treated with the JAK inhibitor tofacitinib showed hair regrowth but experienced worsened facial acne.

This study reports that the metanephrine content was significantly higher in patients with alopecia areata compared to those without the condition.

This study reported that topical azelaic acid cream 20% demonstrated statistically significant efficacy in treating localized alopecia areata of the scalp over 12 weeks, comparable to topical clobetasol ointment 0.05%, suggesting it as a potential therapeutic option.

This study reported that alcoholic cirrhosis patients with zinc deficiency and skin lesions showed rapid symptom improvement with oral zinc sulfate treatment, confirming the diagnosis.

This review discusses common skin appendage diseases, including their pathophysiology and treatments, but does not report new results.

This study conducted at the Pakistan Emirates Military Hospital found that microneedling combined with topical triamcinolone acetonide was significantly more effective and well-tolerated than microneedling alone for treating localized alopecia areata, with 60% of participants achieving complete recovery compared to 5% in the microneedling-only group.

This report describes a 23-year-old man with alopecia areata universalis who experienced severe nail abnormalities, which improved with systemic steroids, benefiting his work as a card illusionist.

This report documents a rare case of familial eyelash trichomegaly and synophrys in three siblings, with one sister also having loose anagen hair syndrome, an unreported association.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

In this placebo-controlled clinical study, a cream containing 4% capryloyl glycine and 1% glycine soy‐fermented extract effectively inhibited ODC1 activity and improved hypertrichosis in 91.7% of Caucasian female patients on the forearms, whereas no improvement was observed with the placebo.

This review emphasizes the importance of accurately distinguishing between diffuse alopecia areata and telogen effluvium in dermatological practice due to differing treatment implications and long-term patient expectations, but reports no new clinical results.

In this case study, a female patient with alopecia areata experienced significant symptom reduction after Ayurvedic treatments including Nasya and Pracchanna karma, suggesting potential effectiveness of this approach for managing autoimmune hair disorders.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.